1. Home
  2. BIRD vs GRDX Comparison

BIRD vs GRDX Comparison

Compare BIRD & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

N/A

Current Price

$1.94

Market Cap

30.1M

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.99

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BIRD
GRDX
Founded
2015
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.1M
28.6M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
BIRD
GRDX
Price
$1.94
$4.99
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 459.6K
107.9K
Earning Date
11-13-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
20.22
★ 21.95
EPS
★ N/A
N/A
Revenue
★ $152,466,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$487.91
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.05
$1.87
52 Week High
$24.31
$6.93

Technical Indicators

Market Signals
Indicator
BIRD
GRDX
Relative Strength Index (RSI) 31.60 54.68
Support Level N/A $2.37
Resistance Level $2.54 $5.04
Average True Range (ATR) 0.14 0.58
MACD -0.06 0.03
Stochastic Oscillator 2.20 44.09

Price Performance

Historical Comparison
BIRD
GRDX

About BIRD Allbirds Inc.

Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: